Recent advances in biosensors for neurodegenerative disease detection

TrAC - Trends in Analytical Chemistry

Volumn 79, Issue , 2016, Pages 363-370

  Ganesh, Hashwin V S ^a   Chow, Ari M ^a   Kerman, Kagan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alpha synuclein; Alzheimer's disease; Amyloid beta; Biosensor; Electrochemical; Neurodegenerative disease; Optical; Parkinson's disease; Prion; Surface plasmon resonance

Indexed keywords

BIOSENSORS; CARBON; CARBON NANOTUBES; CHEMICAL DETECTION; PROTEINS; SEMICONDUCTOR QUANTUM DOTS; SURFACE PLASMON RESONANCE; YARN;

ALZHEIMER'S DISEASE; AMYLOID BETAS; ELECTROCHEMICAL; OPTICAL; PARKINSON'S DISEASE; PRION; SYNUCLEIN;

NEURODEGENERATIVE DISEASES;

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; GOLD NANOPARTICLE; HIGH DENSITY LIPOPROTEIN; LEUCINE RICH REPEAT KINASE 2; MULTI WALLED NANOTUBE; QUANTUM DOT; TAU PROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; APOE2 GENE; APOE3 GENE; APOE4 GENE; BIOSENSOR; CARBOXY TERMINAL SEQUENCE; CHEMOLUMINESCENCE; COMORBIDITY; DIFFERENTIAL PULSE VOLTAMMETRY; DISEASE COURSE; ELECTROCHEMICAL DETECTION; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENETIC RISK; HUMAN; IMMUNOSENSOR; LIMIT OF DETECTION; LOCALIZED SURFACE PLASMON RESONANCE; LRRK2 GENE; NONHUMAN; NUCLEIC ACID HYBRIDIZATION; PARKINSON DISEASE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; QUARTZ CRYSTAL MICROBALANCE; REVIEW; SURFACE PLASMON RESONANCE;

EID: 84964323862     PISSN: 01659936     EISSN: 18793142     Source Type: Journal    
DOI: 10.1016/j.trac.2016.02.012     Document Type: Review

References (76)

1. Chaudhuri T.K., Paul S. Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J. 2006, 273:1331-1349.
2. Dua T. Atlas on Country Resources for Neurological Disorders 2004, WHO.
3. Prince M., Wimo A., Guerchet M., Ali G., Wu Y., Prina M. World Alzheimer Report 2015 2015, Alzheimer's Disease International (ADI), London.
4. Karesh W.B., Cook R.A., Bennett E.L., Newcomb J. Wildlife trade and global disease emergence. Emerg. Infect. Dis 2005, 11:1000-1002.
5. Serrano-Pozo A., Frosch M.P., Masliah E., Hyman B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med 2011, 1:a006189.
6. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
7. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
8. Stine W.B., Dahlgren K.N., Krafft G.A., LaDu M.J. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem 2003, 278:11612-11622.
9. Nishitsuji K., Tomiyama T., Ishibashi K., Ito K., Teraoka R., Lambert M.P., et al. The E693Delta mutation in amyloid precursor protein increases intracellular accumulation of amyloid beta oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. Am. J. Pathol 2009, 174:957-969.
10. Giannakopoulos P., Herrmann F.R., Bussiere T., Bouras C., Kovari E., Perl D.P., et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003, 60:1495-1500.
11. Kondo J., Honda T., Mori H., Hamada Y., Miura R., Ogawara M., et al. The carboxyl third of tau is tightly bound to paired helical filaments. Neuron 1988, 1:827-834.
12. Meraz-Rios M.A., Lira-De Leon K.I., Campos-Pena V., De Anda-Hernandez M.A., Mena-Lopez R. Tau oligomers and aggregation in Alzheimer's disease. J. Neurochem 2010, 112:1353-1367.
13. Kopeikina K.J., Hyman B.T., Spires-Jones T.L. Soluble forms of tau are toxic in Alzheimer's disease. Transl. Neurosci 2012, 3:223-233.
14. Anand R., Gill K.D., Mahdi A.A. Therapeutics of Alzheimer's disease: past, present and future. Neuropharmacology 2014, 76(Pt A):27-50.
15. Lee V.M., Balin B.J., Otvos L., Trojanowski J.Q. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 1991, 251:675-678.
16. Lasagna-Reeves C.A., Castillo-Carranza D.L., Guerrero-Muoz M.J., Jackson G.R., Kayed R. Preparation and characterization of neurotoxic tau oligomers. Biochemistry 2010, 49:10039-10041.
17. Hatters D.M., Peters-Libeu C.A., Weisgraber K.H. Apolipoprotein E structure: insights into function. Trends Biochem. Sci 2006, 31:445-454.
18. Gupta V., Narayanaswami V., Budamagunta M.S., Yamamato T., Voss J.C., Ryan R.O. Lipid-induced extension of apolipoprotein E helix 4 correlates with low density lipoprotein receptor binding ability. J. Biol. Chem 2006, 281:39294-39299.
19. Hatters D.M., Voss J.C., Budamagunta M.S., Newhouse Y.N., Weisgraber K.H. Insight on the molecular envelope of lipid-bound apolipoprotein E from electron paramagnetic resonance spectroscopy. J. Mol. Biol 2009, 386:261-271.
20. Weisgraber K.H., Mahley R.W. Human apolipoprotein E: the Alzheimer's disease connection. FASEB J. 1996, 10:1485-1494.
21. Raber J., Huang Y., Ashford J.W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 2004, 25:641-650.
22. Hirsch-Reinshagen V., Wellington C.L. Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease. Curr. Opin. Lipidol 2007, 18:325-332.
23. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci 1993, 90:1977-1981.
24. Hampel H., Frank R., Broich K., Teipel S.J., Katz R.G., Hardy J., et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov 2010, 9:560-574.
25. Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148:1204-1222.
26. Jankovic J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 2008, 79:368-376.
27. Dickson D.W. Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb. Perspect. Med 2012, 2.
28. Lundvig D., Lindersson E., Jensen P.H. Pathogenic effects of alpha-synuclein aggregation. Brain Res. Mol. Brain Res 2005, 134:3-17.
29. Bennett M.C. The role of alpha-synuclein in neurodegenerative diseases. Pharmacol. Ther 2005, 105:311-331.
30. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:571-576.
31. Wright J.A., Wang X., Brown D.R. Unique copper-induced oligomers mediate alpha-synuclein toxicity. FASEB J. 2009, 23:2384.
32. Uversky V.N. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn 2003, 21:211-234.
33. Davie C.A. A review of Parkinson's disease. Br. Med. Bull 2008, 86:109-127.
34. Shulman J.M., De Jager P.L., Feany M.B. Parkinson's disease: genetics and pathogenesis. Annu. Rev. Pathol 2011, 6:193-222.
35. Aguzzi A., Heikenwalder M. Pathogenesis of prion diseases: current status and future outlook. Nat. Rev. Microbiol 2006, 4:765-775.
36. Chesebro B. Introduction to the transmissible spongiform encephalopathies or prion diseases. Br. Med. Bull 2003, 66:1-20.
37. Zhao Z., Zhu L., Bu X., Ma H., Yang S., Yang Y., et al. Label-free detection of Alzheimer's disease through the ADP3 peptoid recognizing the serum amyloid-beta42 peptide. Chem. Commun. (Camb.) 2015, 51:718-721.
38. Lee Y.K., Lee K.S., Kim W.M., Sohn Y.S. Detection of amyloid-beta42 using a waveguide-coupled bimetallic surface plasmon resonance sensor chip in the intensity measurement mode. PLoS ONE 2014, 9. e98992.
39. Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol 2011, 29:26-32.
40. Xia N., Liu L., Harrington M.G., Wang J., Zhou F. Regenerable and simultaneous surface plasmon resonance detection of abeta(1-40) and abeta(1-42) peptides in cerebrospinal fluids with signal amplification by streptavidin conjugated to an N-terminus-specific antibody. Anal. Chem 2010, 82:10151-10157.
41. Sciacca B., Francois A., Klingler-Hoffmann M., Brazzatti J., Penno M., Hoffmann P., et al. Radiative-surface plasmon resonance for the detection of apolipoprotein E in medical diagnostics applications. Nanomedicine 2013, 9:550-557.
42. Wang R., Minunni M., Tombelli S., Mascini M. A new approach for the detection of DNA sequences in amplified nucleic acids by a surface plasmon resonance biosensor. Biosens. Bioelectron 2004, 20:598-605.
43. Tombelli S., Mascini M., Braccini L., Anichini M., Turner A.P. Coupling of a DNA piezoelectric biosensor and polymerase chain reaction to detect apolipoprotein E polymorphisms. Biosens. Bioelectron 2000, 15:363-370.
44. Vestergaard M., Kerman K., Kim D.K., Ha M.H., Tamiya E. Detection of Alzheimer's tau protein using localised surface plasmon resonance-based immunochip. Talanta 2008, 74:1038-1042.
45. Petryayeva E., Krull U.J. Localized surface plasmon resonance: nanostructures, bioassays and biosensing - a review. Anal. Chim. Acta 2011, 706:8-24.
46. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003, 289:2094-2103.
47. Gagni P., Sola L., Cretich M., Chiari M. Development of a high-sensitivity immunoassay for amyloid-beta 1-42 using a silicon microarray platform. Biosens. Bioelectron 2013, 47:490-495.
48. Ammar M., Smadja C., Ly G.T., Tandjigora D., Vigneron J., Etcheberry A., et al. Chemical engineering of self-assembled Alzheimer's peptide on a silanized silicon surface. Langmuir 2014, 30:5863-5872.
49. Ammar M., Smadja C., Giang Thi Phuong L., Azzouz M., Vigneron J., Etcheberry A., et al. A new controlled concept of immune-sensing platform for specific detection of Alzheimer's biomarkers. Biosens. Bioelectron 2013, 40:329-335.
50. Morales-Narvaez E., Monton H., Fomicheva A., Merkoci A. Signal enhancement in antibody microarrays using quantum dots nanocrystals: application to potential Alzheimer's disease biomarker screening. Anal. Chem 2012, 84:6821-6827.
51. Ma W., Qin L.X., Liu F.T., Gu Z., Wang J., Pan Z.G., et al. Ubiquinone-quantum dot bioconjugates for in vitro and intracellular complex I sensing. Sci. Rep 2013, 3:1537.
52. Ankireddy S.R., Kim J. Selective detection of dopamine in the presence of ascorbic acid via fluorescence quenching of InP/ZnS quantum dots. Int. J. Nanomedicine 2015, 10(Spec Iss):113-119.
53. Yildirim A., Bayindir M. Turn-on fluorescent dopamine sensing based on in situ formation of visible light emitting polydopamine nanoparticles. Anal. Chem 2014, 86:5508-5512.
54. Kruse N., Schulz-Schaeffer W.J., Schlossmacher M.G., Mollenhauer B. Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of alpha-synuclein and other proteins in cerebrospinal fluid. Methods 2012, 56:514-518.
55. Parnetti L., Chiasserini D., Bellomo G., Giannandrea D., De Carlo C., Qureshi M.M., et al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord 2011, 26:1428-1435.
56. Jiayu W., Xiong W., Jiping L., Wensen L., Ming X., Linna L., et al. A rapid method for detection of PrP by surface plasmon resonance (SPR). Arch. Virol 2009, 154:1901-1908.
57. Hossain M.T., Shibata T., Kabashima T., Kai M. Aptamer-mediated chemiluminescence detection of prion protein on a membrane using trimethoxyphenylglyoxal. Anal. Sci 2010, 26:645-647.
58. Azam G., Shibata T., Kabashima T., Kai M. Sensitive chemiluminescence detection of prion protein on a membrane by using a peroxidase-labeled dextran probe. Anal. Sci 2011, 27:715.
59. Zhang H.J., Zheng H.Z., Long Y.J., Xiao G.F., Zhang L.Y., Wang Q.L., et al. Gold nanoparticles as a label-free probe for the detection of amyloidogenic protein. Talanta 2012, 89:401-406.
60. Yu Y., Zhang L., Li C., Sun X., Tang D., Shi G. A method for evaluating the level of soluble beta-amyloid(1-40/1-42) in Alzheimer's disease based on the binding of gelsolin to beta-amyloid peptides. Angew. Chem. Int. Ed. Engl 2014, 53:12832-12835.
61. Fukuyama R., Mizuno T., Mori S., Nakajima K., Fushiki S., Yanagisawa K. Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur. Neurol 2000, 43:155-160.
62. Liu L., Zhao F., Ma F., Zhang L., Yang S., Xia N. Electrochemical detection of beta-amyloid peptides on electrode covered with N-terminus-specific antibody based on electrocatalytic O2 reduction by Abeta(1-16)-heme-modified gold nanoparticles. Biosens. Bioelectron 2013, 49:231-235.
63. Iqbal K., Alonso Adel C., Chen S., Chohan M.O., El-Akkad E., Gong C.X., et al. Tau pathology in alzheimer's disease and other tauopathies. Biochim. Biophys. Acta 2005, 1739:198-210.
64. Esteves-Villanueva J.O., Trzeciakiewicz H., Martic S. A protein-based electrochemical biosensor for detection of tau protein, a neurodegenerative disease biomarker. Analyst 2014, 139:2823-2831.
65. Cheng X.R., Hau B.Y., Endo T., Kerman K. Au nanoparticle-modified DNA sensor based on simultaneous electrochemical impedance spectroscopy and localized surface plasmon resonance. Biosens. Bioelectron 2014, 53:513-518.
66. Marrazza G., Chiti G., Mascini M., Anichini M. Detection of human apolipoprotein E genotypes by DNA electrochemical biosensor coupled with PCR. Clin. Chem 2000, 46:31-37.
67. Medina-Sanchez M., Miserere S., Morales-Narvaez E., Merkoci A. On-chip magneto-immunoassay for Alzheimer's biomarker electrochemical detection by using quantum dots as labels. Biosens. Bioelectron 2014, 54:279-284.
68. de la Escosura-Muniz A., Plichta Z., Horak D., Merkoci A. Alzheimer's disease biomarkers detection in human samples by efficient capturing through porous magnetic microspheres and labelling with electrocatalytic gold nanoparticles. Biosens. Bioelectron 2015, 67:162-169.
69. Erdem A., Congur G. Label-free voltammetric detection of MicroRNAs at multi-channel screen printed array of electrodes comparison to graphite sensors. Talanta 2014, 118:7-13.
70. Yue H.Y., Huang S., Chang J., Heo C., Yao F., Adhikari S., et al. ZnO nanowire arrays on 3D hierachical graphene foam: biomarker detection of Parkinson's disease. ACS Nano 2014, 8:1639-1646.
71. Sierks M.R., Chatterjee G., McGraw C., Kasturirangan S., Schulz P., Prasad S. CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr. Biol. (Camb) 2011, 3:1188-1196.
72. An Y., Tang L., Jiang X., Chen H., Yang M., Jin L., et al. A photoelectrochemical immunosensor based on Au-doped TiO2 nanotube arrays for the detection of alpha-synuclein. Chemistry (Easton) 2010, 16:14439-14446.
73. Wustoni S., Hideshima S., Kuroiwa S., Nakanishi T., Hashimoto M., Mori Y., et al. Sensitive electrical detection of human prion proteins using field effect transistor biosensor with dual-ligand binding amplification. Biosens. Bioelectron 2015, 67:256-262.
74. Miodek A., Castillo G., Hianik T., Korri-Youssoufi H. Electrochemical aptasensor of cellular prion protein based on modified polypyrrole with redox dendrimers. Biosens. Bioelectron 2014, 56:104-111.
75. Miodek A., Castillo G., Hianik T., Korri-Youssoufi H. Electrochemical aptasensor of human cellular prion based on multiwalled carbon nanotubes modified with dendrimers: a platform for connecting redox markers and aptamers. Anal. Chem 2013, 85:7704-7712.
76. Hianik T., Porfireva A., Grman I., Evtugyn G. EQCM biosensors based on DNA aptamers and antibodies for rapid detection of prions. Protein Pept. Lett 2009, 16:363-367.